FDA snubs Zogenix's anti-seizure drug, not happy with some sloppy, inadequate R&D work
Nine months after Zogenix got a stock rally $ZGNX going by touting late-stage data for a new drug to prevent seizures due to Dravet syndrome …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
